Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.11 | 1.87 |
NAV | ₹10.71 | ₹40.53 |
Fund Started | 29 Oct 2024 | 25 Jun 2018 |
Fund Size | ₹29.14 Cr | ₹6226.82 Cr |
Exit Load | Exit load of 1%, if redeemed within 15 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | - | 6.41% |
3 Year | - | 27.61% |
5 Year | - | 20.92% |
1 Year
3 Year
5 Year
Equity | 99.66% | 97.55% |
Cash | 0.34% | 2.45% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Fortis Healthcare Ltd. | 9.59% |
Lupin Ltd. | 8.77% |
Laurus Labs Ltd. | 6.20% |
Alkem Laboratories Ltd. | 5.80% |
Aurobindo Pharma Ltd. | 5.75% |
Glenmark Pharmaceuticals Ltd. | 5.58% |
Mankind Pharma Ltd. | 5.22% |
Biocon Ltd. | 3.89% |
Ipca Laboratories Ltd. | 3.53% |
Krishna Institute of Medical Sciences Ltd | 3.27% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.58% |
Dr. Reddy's Laboratories Ltd. | 9.10% |
Divi's Laboratories Ltd. | 8.75% |
Aurobindo Pharma Ltd. | 8.25% |
Cipla Ltd. | 6.92% |
Lupin Ltd. | 5.43% |
Alkem Laboratories Ltd. | 4.05% |
Biocon Ltd. | 3.11% |
Gland Pharma Ltd. | 2.97% |
Mankind Pharma Ltd. | 2.95% |
Name | Swapnil P Mayekar | Dharmesh Kakkad |
Start Date | 05 Jun 2025 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 29 Oct 2024 | 25 Jun 2018 |
Description
Launch Date